Pathology: mNSCLC - L1 - PDL1 positive;
| mNSCLC - L1 - PDL1 positive | |||||||||||||||
| IMpower-110 (TC1/2/3 or IC1/2/3), 2020 | IMpower-110 (TC3 or IC3), 2020 | IMpower-110 (TC2/3 or IC2/3), 2020 | EMPOWER lung1 (PDL1>50%), 2021 | MYSTIC (D ; PDL1>25%), 2020 | MYSTIC (DT ; PDL1>25%), 2020 | CheckMate 026 (PDL1>1%), 2016 | CheckMate 026 (PDL1>5%), 2016 | CheckMate 227 (NI vs C ; PDL1>1%), 2018 | KEYNOTE-042 (PDL1>20%), 2019 | KEYNOTE-024 (PDL1>50%), 2016 | KEYNOTE-042 (PDL1>1%), 2019 | KEYNOTE-042 (PDL1>50%), 2019 | KEYNOTE-598, 2020 | ||
| pembrolizumab alone | 4 | T1 | T1 | T1 | T1 | ||||||||||
| atezolizumab alone | 3 | T1 | T1 | T1 | |||||||||||
| nivolumab alone | 2 | T1 | T1 | ||||||||||||
| cemiplimab | 1 | T1 | |||||||||||||
| durvalumab alone | 1 | T1 | |||||||||||||
| durvalumab plus tremelimumab | 1 | T1 | |||||||||||||
| pembrolizumab plus ipilimumab | 1 | T1 | |||||||||||||
| nivolumab plus ipilimumab | 1 | T1 | |||||||||||||
| pembrolizumab plus placebo | 0 | T0 | |||||||||||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | ||
| pemetrexed plus platin | 0 | T0 | |||||||||||||